ClinicalTrials.gg
RecruitingNCT07197736DELINEATEUpdated Apr 16, 2026

DELINEATE-Prospective

An observational study in Valve Disease, Aortic, Mitral Regurgitation (MR) and Aortic Stenosis, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Columbia University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Aortic Valve Disease with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Aortic Valve Disease · United States.

Planned enrollment
13th of 16
50 · median 109
Started
2026
with 1 other
Observational
16 of 47
3 open now
Primary completion
2027-10
later than 18 of 22 live
Registered
46th of 47
by date

Among the 47 studies in Aortic Valve Disease with a site in United States, this one is the 13th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2026, is one of 16 observational ones, reaches primary completion later than 18 of the 22 other live ones, and was the 46th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

12 of the 47 studies in Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

Heart disease is the leading cause of death in the United States, and echocardiography (or "echo") is the most common way doctors look at the heart. Echo is safe, painless, and can detect major heart problems, including weak heart pumping and valve disease.

Valve disease, especially aortic stenosis (narrowing) and mitral regurgitation (leakage), is common in older adults but often goes undiagnosed. While echo is the main tool for finding valve problems, it takes time, requires expert training, and results can vary between readers.

Recent advances in artificial intelligence (AI), especially deep learning (DL), have shown promise in automatically analyzing heart images. However, past research hasn't fully tackled key echo techniques-like color Doppler and spectral Doppler-that are crucial for measuring how blood moves through heart valves. AI tools also face challenges in being used in everyday medical practice because of workflow issues, lack of real-world testing, and concerns about how the algorithms make decisions.

At Columbia University Irving Medical Center, researchers have built a large database of heart tests over the last six years and developed AI programs to analyze echocardiograms. The current study will test whether providing AI analysis to cardiologists in real time during echo reading can make the process faster and more consistent.

Read the detailed description

In a prior Columbia University study, a series of deep learning algorithms analyzing echocardiograms is in development. These algorithms include, but are not limited to, algorithms that enable view classification, structure identification, left ventricle (LV) dimension measurements, Left Ventricular Ejection Fraction (LVEF) determination, left atrium (LA) volume assessments, and valvular heart disease diagnosis. Briefly, these algorithms are based on architectures shown to be useful in image and video analysis, including ones specific to echocardiography interpretation. Algorithms based off these architectures can be generalized to interpretation of video-based echocardiogram data such as valvular regurgitation assessment. As part of this study protocol, these models will continue to be developed using patient echocardiogram data. This study aims to create an automated, end-to-end system that can deliver deep learning analyses of echocardiograms to the interpreting cardiologist in real-time. If successful, this program could enable improvements in echocardiography reading efficiency and reliability.

03

Conditions studied

  • Valve Disease, Aortic
  • Mitral Regurgitation (MR)
  • Aortic Stenosis
  • Valvular Heart Disease
  • Tricuspid Regurgitation (TR)
  • Aortic Regurgitation

Keywords

  • artificial intelligence
  • deep learning
  • valvular heart disease
  • echocardiography
  • cardiovascular disease
  • mitral regurgitation
  • aortic stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Board-certified attending cardiologists at Columbia University, ColumbiaDoctors, or NewYork-Presbyterian Hospital who interpret transthoracic echocardiograms in the Columbia echocardiography laboratory and have provided informed consent to participate

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewYork Presbyterian Hospital who reads transthoracic echocardiograms in the Columbia echocardiography laboratory
  • Provided to take part in the questionnaires or pivotal study

Exclusion criteria

Exclusion Criteria:

  • Physician in training (cardiology fellow or advanced imaging fellow)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intervention Group

    Studies meeting the following criteria will undergo adjudication by an expert panel: Moderate, moderate-severe, or severe mitral, aortic, or tricuspid regurgitation by physician or AI model assessment. Discrepancy between physician and AI interpretations, where AI-assessed severity is greater than the physician-assessed severity (i.e. indicates that more valvular regurgitation is present)

  • Control Group

    A stratified random sample of cases will be selected to match the distribution of AI-flagged cases by physician-assessed valvular regurgitation severity and will undergo the same expert panel adjudication.

06

What researchers measure

Primary outcomes

  1. Proportion of Clinically Meaningful Reclassification by Panel Review

    Proportion of cases where the expert panel reclassifies valvular regurgitation severity by at least one grade (upgrade or downgrade). The proportion will be calculated as the number of cases with reclassification ÷ total number of cases reviewed.

    Time frame: 18 months

Secondary outcomes

  1. Proportion of Cases with AI-Based Reclassification Leading to a Change in Clinical Management

    The proportion will be calculated as the number of cases with any management change ÷ total number of cases reviewed.

    Time frame: 18 months

  2. Proportion of Cases with AI-Based Reclassification Leading to Referral to a Valve Specialist or Surgeon

    Definition: The proportion will be calculated as the number of cases referred to a valve specialist or surgeon ÷ total number of cases reviewed.

    Time frame: 18 months

  3. Proportion of Cases with AI-Based Reclassification Leading to a Change in Frequency of Follow-Up Echocardiography

    The proportion will be calculated as the number of cases with a change in recommended follow-up echocardiography frequency ÷ total number of cases reviewed.

    Time frame: 18 months

  4. Proportion of Cases with AI-Based Reclassification Leading to Referral for Further Testing (TEE or Cardiac MRI)

    The proportion will be calculated as the number of cases referred for further testing with TEE or cardiac MRI ÷ total number of cases reviewed.

    Time frame: 18 months

Other outcomes

  1. Concordance Between AI and Panel Review

    Proportion of cases where AI classification agrees with expert panel review of valvular regurgitation severity.

    Time frame: 18 months

  2. Concordance Between Cardiologist Clinical Read and Panel Review

    Proportion of cases where cardiologist clinical interpretation agrees with expert panel review of valvular regurgitation severity.

    Time frame: 18 months

  3. Comparison of Concordance Rates (AI vs Cardiologist) Against Panel Review

    Difference between the concordance rate of AI vs panel review and the concordance rate of cardiologist clinical read vs panel review.

    Time frame: 18 months

  4. Inter-Reader Agreement for Categorical Echocardiographic Measures

    Agreement between independent cardiologist readers for categorical variables (e.g., severity of valvular regurgitation) will be quantified using Cohen's kappa statistic.

    Time frame: 18 months

  5. Inter-Reader Agreement for Continuous Echocardiographic Measures

    Agreement between independent cardiologist readers for continuous measures (e.g., left ventricular ejection fraction \[LVEF\] category) will be quantified using the intraclass correlation coefficient (ICC)

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Patient privacy and confidentiality: Even with de-identification, sharing detailed health data could risk re-identification of participants. Regulatory restrictions: Institutional Review Boards (IRBs), HIPAA rules, or local laws may limit data sharing, especially for sensitive health information like echocardiograms. Consent limitations: If participants did not explicitly consent to broad data sharing at enrollment, the study cannot ethically or legally provide their IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2027, 17 months later.

Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 17 months is below that.

Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Sep 29, 2025
StartEst.
Apr 15, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07197736
Collaborators
American Heart Association
Responsible party
Pierre Elias (Assistant Professor of Medicine in the Department of Biomedical Informatics, Columbia University) — Principal investigator
First posted
Sep 29, 2025
Start date
Apr 15, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Heidi S Hartman, MD
Contact
hl2738@cumc.columbia.edu
212-305-3068
Michelle Castillo, BS
Contact
mc5067@cumc.columbia.edu
212-305-9161
Pierre A Elias, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion